n6022 and Bronchial-Hyperreactivity

Patients with asthma demonstrate depletion of the endogenous bronchodilator GSNO and upregulation of GSNOR.. An exploratory proof of concept clinical study of N6022 in mild asthma to determine the potential bronchoprotective effects of GSNOR inhibition. Mechanistic studies aimed to provide translational evidence of effect.. Fourteen mild asthma patients were treated with intravenous N6022 (5 mg) or placebo and observed for 7 days, with repeated assessments of the provocative dose of methacholine causing a 20% fall in FEV1 (methacholine PC. In this early phase exploratory proof of concept trial in asthma, N6022 did not significantly alter methacholine PC

Topics: Administration, Intravenous; Adult; Aldehyde Oxidoreductases; Asthma; Benzamides; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoconstrictor Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Methacholine Chloride; Middle Aged; Placebos; Proof of Concept Study; Pyrroles; S-Nitrosoglutathione; Treatment Outcome; Young Adult